PDCD1 and renal cell carcinoma: Blockade of PD-1 by anti-PD-1 antibody has been tested in phase I. The largest cohort tested included 296 patients with advanced solid tumours, including melanoma, NSCLC, renal cell carcinoma, prostate cancer, and colorectal cancer.